ITOS
NASDAQiTeos Therapeutics Inc.
Price$10.17+0.14 (+1.40%)
2025-06-092025-08-29
Latest news
25 items- SECSEC Form 15-12G filed by iTeos Therapeutics Inc.15-12G - iTeos Therapeutics, Inc. (0001808865) (Filer)
- SECSEC Form EFFECT filed by iTeos Therapeutics Inc.EFFECT - iTeos Therapeutics, Inc. (0001808865) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by iTeos Therapeutics Inc.SCHEDULE 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)
- INSIDERChief Operating Officer Call Matthew closing all direct ownership in the company (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- INSIDERChief Executive Officer Detheux Michel closing all direct ownership in the company (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- INSIDERSEC Form 4 filed by Director Lee David K4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- INSIDERChief Medical Officer Feltquate David closing all direct ownership in the company (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- INSIDERChief Scientific Officer Mcgrath Yvonne closing all direct ownership in the company (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- INSIDERChief Financial Officer Gall Matthew closing all direct ownership in the company (SEC Form 4)4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- INSIDERSEC Form 4 filed by Director Hallal David4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- INSIDERSEC Form 4 filed by Director Rhoads Ann D4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
- SECSEC Form S-8 POS filed by iTeos Therapeutics Inc.S-8 POS - iTeos Therapeutics, Inc. (0001808865) (Filer)
- SECSEC Form S-8 POS filed by iTeos Therapeutics Inc.S-8 POS - iTeos Therapeutics, Inc. (0001808865) (Filer)
- SECSEC Form S-8 POS filed by iTeos Therapeutics Inc.S-8 POS - iTeos Therapeutics, Inc. (0001808865) (Filer)
- SECSEC Form S-8 POS filed by iTeos Therapeutics Inc.S-8 POS - iTeos Therapeutics, Inc. (0001808865) (Filer)
- SECSEC Form S-8 POS filed by iTeos Therapeutics Inc.S-8 POS - iTeos Therapeutics, Inc. (0001808865) (Filer)
- SECSEC Form S-8 POS filed by iTeos Therapeutics Inc.S-8 POS - iTeos Therapeutics, Inc. (0001808865) (Filer)
- SECSEC Form POS AM filed by iTeos Therapeutics Inc.POS AM - iTeos Therapeutics, Inc. (0001808865) (Filer)
- SECSEC Form 25-NSE filed by iTeos Therapeutics Inc.25-NSE - iTeos Therapeutics, Inc. (0001808865) (Subject)
- SECiTeos Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant8-K - iTeos Therapeutics, Inc. (0001808865) (Filer)
- SECAmendment: SEC Form SC 14D9/A filed by iTeos Therapeutics Inc.SC 14D9/A - iTeos Therapeutics, Inc. (0001808865) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by iTeos Therapeutics Inc.SCHEDULE 13G/A - iTeos Therapeutics, Inc. (0001808865) (Subject)
- SECSEC Form 10-Q filed by iTeos Therapeutics Inc.10-Q - iTeos Therapeutics, Inc. (0001808865) (Filer)
- SECSEC Form SC 14D9 filed by iTeos Therapeutics Inc.SC 14D9 - iTeos Therapeutics, Inc. (0001808865) (Subject)
- SECSEC Form SCHEDULE 13G filed by iTeos Therapeutics Inc.SCHEDULE 13G - iTeos Therapeutics, Inc. (0001808865) (Subject)
ITOS FAQ
7 questionsWhat does iTeos Therapeutics Inc. do?
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent...Where does ITOS stock trade?
iTeos Therapeutics Inc. (ITOS) is listed on NASDAQ.What sector and industry is ITOS in?
iTeos Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did iTeos Therapeutics Inc. go public?
iTeos Therapeutics Inc. (ITOS) completed its IPO in 2020.What are analysts saying about ITOS?
iTeos Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Equal Weight with a $1200.00 price target on 2025-05-28. Recent price targets range from $900.00 to $3100.00.What companies are similar to ITOS?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ITOS side-by-side with any of them on Quantisnow.How can I track ITOS on Quantisnow?
Quantisnow aggregates iTeos Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ITOS to receive live email and push alerts on every new disclosure.